BeOne Medicines insider sells ADSs after option exercises

BeOne Medicines Ltd. executive SVP and General Counsel reported stock transactions in the company’s American Depositary Shares (ADSs).

Accepted by SEC EDGAR 12/12/2025 - 04:56 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

BeOne Medicines Ltd. executive SVP and General Counsel reported stock transactions in the company’s American Depositary Shares (ADSs). On December 10 and 11, 2025, the insider exercised stock options and then sold shares, as shown in the Form 4 tables. The filing shows multiple option exercises into ADSs, followed by open-market sales of 332 ADSs at $318.28 on December 10 and 332 ADSs at $325.00 on December 11.

Each ADS represents 13 ordinary shares, and the derivative securities are stock options with exercise prices of $14.96, $16.41, and $12.23 per ordinary share. The options vest over four-year schedules with initial 25% vesting and the remainder in monthly installments, with potential accelerated vesting upon certain termination events. The sale transactions were carried out under a Rule 10b5-1 trading plan adopted on May 14, 2025.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 14 txns

Insider Lee Chan Henry

Role SVP, General Counsel

Sold 664 shs ($214K)

Approx. gross sale proceeds $214K

Approx. exercise cost $127K

Type	Security	Shares	Price	Value
Exercise	Share Option (Right to Buy)	1,313	$0.00	$0.00
Exercise	Share Option (Right to Buy)	1,729	$0.00	$0.00
Exercise	Share Option (Right to Buy)	1,274	$0.00	$0.00
Exercise	American Depositary Shares	101	$194.47	$20K
Exercise	American Depositary Shares	133	$213.32	$28K
Exercise	American Depositary Shares	98	$159.03	$16K
Sale	American Depositary Shares	332	$325.00	$108K
Exercise	Share Option (Right to Buy)	1,313	$0.00	$0.00
Exercise	Share Option (Right to Buy)	1,729	$0.00	$0.00
Exercise	Share Option (Right to Buy)	1,274	$0.00	$0.00
Exercise	American Depositary Shares	101	$194.47	$20K
Exercise	American Depositary Shares	133	$213.32	$28K
Exercise	American Depositary Shares	98	$159.03	$16K
Sale	American Depositary Shares	332	$318.28	$106K
Holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 254,215 contracts (Direct); American Depositary Shares — 0 shares (Direct); Ordinary Shares — 223,106 shares (Direct)

Footnotes (6)

1. F1. Each American Depositary Share represents 13 Ordinary Shares.
2. F2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.
3. F3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
4. F4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
5. F5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
6. F6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did BeOne Medicines Ltd. (ONC) disclose in this filing?

The filing reports that the SVP and General Counsel of BeOne Medicines Ltd. exercised stock options and then sold ADSs in open-market transactions on December 10 and 11, 2025.

How many BeOne Medicines (ONC) ADSs were sold and at what prices?

The reporting person sold 332 ADSs at $318.28 on December 10, 2025 and 332 ADSs at $325.00 on December 11, 2025.

What is the relationship between BeOne Medicines ADSs and ordinary shares?

According to the filing, each American Depositary Share represents 13 ordinary shares of BeOne Medicines Ltd.

Were the BeOne Medicines (ONC) insider sales under a Rule 10b5-1 trading plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.

What stock options does the BeOne Medicines (ONC) insider hold and at what exercise prices?

The reporting person holds share options to buy ordinary shares with exercise prices of $14.96, $16.41, and $12.23 per ordinary share, as listed in the derivative securities table.

How do the BeOne Medicines (ONC) stock options vest for this insider?

The filing explains that the option grants vest over four years, with 25% vesting on a specified initial date and the remaining shares vesting in 36 equal monthly installments, subject to continued service and potential accelerated vesting upon certain termination events.

What position does the reporting person hold at BeOne Medicines Ltd. (ONC)?

The reporting person is an officer of BeOne Medicines Ltd., serving as SVP, General Counsel.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Chan Henry

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL V8 4051

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								223,106	D
American Depositary Shares(1)	12/10/2025		M		101	A	$194.47	101	D
American Depositary Shares(1)	12/10/2025		M		133	A	$213.32	234	D
American Depositary Shares(1)	12/10/2025		M		98	A	$159.03	332	D
American Depositary Shares(1)	12/10/2025		S(2)		332	D	$318.28	0	D
American Depositary Shares(1)	12/11/2025		M		101	A	$194.47	101	D
American Depositary Shares(1)	12/11/2025		M		133	A	$213.32	234	D
American Depositary Shares(1)	12/11/2025		M		98	A	$159.03	332	D
American Depositary Shares(1)	12/11/2025		S(2)		332	D	$325	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$14.96(3)	12/10/2025		M			1,313	(4)	08/04/2032	Ordinary Shares	1,313	$0	34,385	D
Share Option (Right to Buy)	$16.41(3)	12/10/2025		M			1,729	(5)	06/14/2033	Ordinary Shares	1,729	$0	102,206	D
Share Option (Right to Buy)	$12.23(3)	12/10/2025		M			1,274	(6)	06/04/2034	Ordinary Shares	1,274	$0	121,940	D
Share Option (Right to Buy)	$14.96(3)	12/11/2025		M			1,313	(4)	08/04/2032	Ordinary Shares	1,313	$0	33,072	D
Share Option (Right to Buy)	$16.41(3)	12/11/2025		M			1,729	(5)	06/14/2033	Ordinary Shares	1,729	$0	100,477	D
Share Option (Right to Buy)	$12.23(3)	12/11/2025		M			1,274	(6)	06/04/2034	Ordinary Shares	1,274	$0	120,666	D

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.

3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.